Loading
A phase 2 trial of Bevacizumab, Cemiplimab, Fianlimab in ovarian cancer, run by Regeneron Pharmaceuticals, now recruiting.
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT06787612 by Regeneron Pharmaceuticals, with 297 participants planned, started 2025-05-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ubamatamab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Ubamatamab, Regeneron, Cemiplimab, Ovarian cancer.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/